Featured Research

from universities, journals, and other organizations

Parkinson's Drugs Undergoing Tests

April 22, 2007
Thomas Jefferson University
Jefferson researchers are participating in a global study to extend effectiveness of drug for Parkinson's.

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

Related Articles

"As time goes on and the disease progresses, the off periods, that is, time during which the medicine is not working at its best, come more frequently as on periods, or times during which patients experience their best response to the drug, last for shorter periods of time," explained Jay S. Schneider, PhD, who heads the Parkinson's Disease Research Unit at Thomas Jefferson University Hospital.

Parkinson's disease gradually destroys brain cells that produce dopamine. As dopamine levels drop, symptoms increase: tremors in the arms, legs and face; periodically stiff or frozen limbs; slow movement, particularly a shuffling gait; and impaired balance and coordination.

Dr. Schneider, Professor of Pathology, Anatomy and Cell Biology and Neurology at Jefferson Medical College of Thomas Jefferson University, and movement disorder specialists Tsao-Wei Liang, M.D., Assistant Professor of Neurology, Jefferson, and Daniel Erik Kremens, M.D., J.D., Assistant Professor of Neurology, Jefferson, are spearheading a new clinical trial to test a new anti-Parkinson's drug in an attempt to decrease such off-time experiences and extend L-dopa's effectiveness.

The study will evaluate whether a drug, E2007, can significantly lengthen the time that a patient's L-dopa medication is effective, reducing both the amount of off time during the day, as well as other unwanted side effects of L-dopa treatment. E2007 is non-dopaminergic drug that acts on a subclass of receptors called the AMPA receptors, which mediate fast synaptic transmission in the central nervous system.

Standard treatments for Parkinson's disease focus on restoring the cellular communication that controls muscle movement by replacing lost dopamine with L-dopa. While this therapy works well for a while, it can't stop the disease's inevitable march - and the patient's decline. While one current strategy is to focus on neuroprotective agents to modify disease progression, another is to use so-called "adjuncts" that can have modest effects on patients' off-times, when L-dopa can be ineffective for brief periods.

"The hope is that by altering dopamine transmission through the modulating the activity of AMPA receptors, there will be measurable effects on the dopamine system," said Dr. Liang.

The study is designed for patients with more advanced Parkinson's who have been taking L-dopa for some time and are now experiencing fluctuations in its effectiveness.

Individuals must have at least two hours of off time a day. Groups of patients will receive either one of two dosages of the drug or a placebo. The trial is also aimed at evaluating E2007's safety, as well as how patients tolerate it. The study will involve approximately 700 patients at about 150 centers across the U.S., Canada, Australia, New Zealand and South America. Jefferson hopes to recruit at least 12 patients.

"It's an interesting approach and an exciting trial because it is exploring a drug in a new therapeutic category," said Dr. Kremens."L-dopa is still the gold standard and we haven't come up with a better dopamine agonist as yet."

Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.

Cite This Page:

Thomas Jefferson University. "Parkinson's Drugs Undergoing Tests." ScienceDaily. ScienceDaily, 22 April 2007. <www.sciencedaily.com/releases/2007/04/070418125437.htm>.
Thomas Jefferson University. (2007, April 22). Parkinson's Drugs Undergoing Tests. ScienceDaily. Retrieved January 26, 2015 from www.sciencedaily.com/releases/2007/04/070418125437.htm
Thomas Jefferson University. "Parkinson's Drugs Undergoing Tests." ScienceDaily. www.sciencedaily.com/releases/2007/04/070418125437.htm (accessed January 26, 2015).

Share This

More From ScienceDaily

More Mind & Brain News

Monday, January 26, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

How Technology Is Ruining Snow Days For Students

How Technology Is Ruining Snow Days For Students

Newsy (Jan. 25, 2015) More schools are using online classes to keep from losing time to snow days, but it only works if students have Internet access at home. Video provided by Newsy
Powered by NewsLook.com
Weird Things Couples Do When They Lose Their Phone

Weird Things Couples Do When They Lose Their Phone

BuzzFeed (Jan. 24, 2015) Did you back it up? Do you even know how to do that? Video provided by BuzzFeed
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com
Amazing Technology Allows Blind Mother to See Her Newborn Son

Amazing Technology Allows Blind Mother to See Her Newborn Son

RightThisMinute (Jan. 23, 2015) Not only is Kathy seeing her newborn son for the first time, but this is actually the first time she has ever seen a baby. Kathy and her sister, Yvonne, have been legally blind since childhood, but thanks to an amazing new technology, eSight glasses, which gives those who are legally blind the ability to see, she got the chance to see the birth of her son. It&apos;s an incredible moment and an even better story. Video provided by RightThisMinute
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins